ASX AnnouncementNeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments • The collaboration will evaluate the ability of NeoImmuneTech’s immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing.• The combination potential of azer-cel and NT-I7 to increase the number and cancer-fighting properties of the patients own T cells during their treatment with azer-cel, will be evaluated in preclinical work. Sydney, Australia December 12, 2023 AEDT and Rockville, MD (USA), December 11, 2023 EST: Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, and NeoImmuneTech, Inc. (“NIT”), (KOSDAQ: 950220) a clinical-stage T-cell- focused biopharmaceutical company, today announced a strategic collaboration to evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T cell amplifier “Fc-fused recombinant human interleukin-7”, NT-I7, for the treatment of cancer.Azer-cel is an allogeneic CD19 CAR T cell therapy program with extensive clinical data and a potentially fast-to-market development strategy. Azer-cel has demonstrated clinically meaningful activity with an acceptable safety profile in blood cancers such as lymphoma and leukemia.NT-I7 (efineptakin alfa) is the only long-acting human IL-7 cytokine1 in clinical stage development. NT-I7 plays a key role in T cell development and survival, boosts cancer fighting T cell numbers, their health, and functionality to enhance immune function and potentially provides improved cancer fighting benefits to patients. NT-I7 exhibits favorable stability, activity and safety profiles on patient dosing compared with naturally occurring IL-7, making it an ideal combination partner for cell therapy drugs like azer-cel
IMU Price at posting:
6.8¢ Sentiment: Hold Disclosure: Held
(20min delay)